RAPT Therapeutics Inc (RAPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.46 Million) by net assets ($151.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RAPT equity financing ratio to measure how much of total assets are equity-financed.
RAPT Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can RAPT Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.
RAPT Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAPT Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hebei Hengshui Laobaigan Liquor Co Ltd
SHG:600559
|
-0.012x |
|
Iljin Electric Co
KO:103590
|
-0.143x |
|
Tootsie Roll Industries Inc
NYSE:TR
|
0.012x |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
0.022x |
|
Lindblad Expeditions Holdings Inc
NASDAQ:LIND
|
-0.315x |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
0.069x |
|
Ams AG
SW:AMS
|
N/A |
|
Titan Wind Energy Suzhou
SHE:002531
|
0.018x |
Annual Cash Flow Conversion Efficiency for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see RAPT Therapeutics Inc (RAPT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $189.90 Million | $-83.30 Million | -0.439x | +33.54% |
| 2023-12-31 | $147.03 Million | $-97.05 Million | -0.660x | -128.65% |
| 2022-12-31 | $245.17 Million | $-70.77 Million | -0.289x | +11.84% |
| 2021-12-31 | $186.38 Million | $-61.03 Million | -0.327x | +15.76% |
| 2020-12-31 | $104.18 Million | $-40.49 Million | -0.389x | +19.89% |
| 2019-12-31 | $73.12 Million | $-35.47 Million | -0.485x | +5.78% |
| 2018-12-31 | $64.00 Million | $-32.95 Million | -0.515x | -218.47% |
| 2017-12-31 | $-62.41 Million | $-27.12 Million | 0.435x | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more